24 results
Thumbnail

D1.90 - Remission of asthma on biological therapy: one center experience

Thumbnail

D1.98 - MV130 drives the differentiation of human monocytes into dendritic cells with antiallergic properties

Thumbnail

D1.102 - Md

Thumbnail

D1.88 - Mepolizumab and intestinal parasitic infection: A case report

Thumbnail

D1.91 - Baseline characteristics and main clinical outcomes of patients receiving tezepelumab in the framework of use in Special Situations prior to commercialization in Spain (T-ROSS Study)

Thumbnail

D1.92 - Results from the EGPAware Delphi study on Red Flags for Suspicion of Eosinophilic Granulomatosis with Polyangiitis (EGPA): current management in Europe

Thumbnail

D1.93 - ICS use trajectories in severe asthma patients on benralizumab: real-life data from 3-years follow-up

Thumbnail

D1.94 - Impact of overweight and obesity on clinical remission and Response to Biologics in Severe Asthma Patients

Thumbnail

D1.95 - Dupilumab-induced eosinophilia: a transient effect

Thumbnail

D1.96 - Impact of Dupilumab-induced Eosinophilia on Pulmonary Function Tests and Patient Reported Outcomes Measures (PROMs)

Thumbnail

D1.99 - Exploring the relationship between 6 minutes walk test (6MWT) performance and lung function in Severe Asthma and CRSwNP

Thumbnail

D1.422 - A service review of the complex COVID-19 vaccination service

Thumbnail

D1.425 - Familial Cold Autoinflammatory Syndrome Post COVID-19 Vaccine: A Case Report

Thumbnail

D1.423 - Listening to Urticaria Patients Through Social Media: Analyzing the Impact of the COVID-19 Pandemic

Thumbnail

D1.424 - Clinical-epidemiological profile of patients with Post-Covid syndrome followed at a medical school outpatient clinic

Thumbnail

D1.426 - Cellular immunity profile in patients with urolithiasis in the presence of post-Covid syndrome

Thumbnail

D3.389 - Deep Learning-Based Real-Time Identification of Wheezing in Lung Sounds: Applications in Disease Prediction and Early Intervention

Thumbnail

D3.390 - Rationale and Design for ALPHA-ORBIT: a phase 3 trial of navenibart, a monoclonal antibody inhibitor of plasma kallikrein for participants with hereditary angioedema (HAE)

Thumbnail

D3.391 - Results from the ALPHA-STAR Trial, a Phase 1b/2 Single and Multiple Dose Study to Assess the Safety, Tolerability, Clinical Activity, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Navenibart in Participants with Hereditary Angioedema (HAE)

Thumbnail

D3.392 - What information and education is crucial for people with food allergies?